LanzaTech went public via a SPAC merger with AMCI Acquisition II in a $1.8bn deal.

LanzaTech, a provider of a bio-processing platform, went public via a SPAC merger with AMCI Acquisition II in a $1.8bn deal with participation from AMCI, ArcelorMittal, BASF, K1W1, Khosla Ventures, Mitsui, New Zealand Superannuation Fund, Oxy Low Carbon Ventures, Primetals Technologies, SHV Energy and Trafigura. “LanzaTech’s revolutionary, commercially scaled technology offering, top quality team led by Chairwoman and CEO, Jennifer Holmgren, and visible path to rapid, profitable growth in the near term, provided all the elements necessary for a successful transaction in line with the original strategy we established at the time of our founding. We are very excited by the tremendous opportunities presented by LanzaTech as its CCT technology is deployed at scale.” Nimesh Patel, AMCI Acquisition CEO.